[Nongonococcal urethritis treatment in men with avelox (moxifloxacin)].
The role of urogenical infection in males in present-day urology is demonstrated with a focus on fluoroquinolones efficacy in combined treatment of urogenital infection. The mechanism of action, pharmacokinetics, the spectrum of antimicrobial activity of a novel fluoroquinolone drug avelox are detailed. Avelox use in combined therapy of mono- and mixed infections caused by ureaplasmas, chlamidias, mycoplasms is illustrated by original experience of the authors. Avelox is well tolerated and safe.
Aboian
I A
IA
Pavlov
S V
SV
Miroshnichenko
V I
VI
Shestel'
A N
AN
D000293:Adolescent; D000328:Adult; D000368:Aged; D000890:Anti-Infective Agents / Q000627:therapeutic use*; D001372:Aza Compounds / Q000627:therapeutic use*; D024841:Fluoroquinolones; D006801:Humans; D008297:Male; D008875:Middle Aged; D000077266:Moxifloxacin; D011804:Quinolines / Q000627:therapeutic use*; D016896:Treatment Outcome; D014526:Urethritis / Q000188:drug therapy* / Q000382:microbiology / Q000469:parasitology; D014552:Urinary Tract Infections / Q000188:drug therapy*
D000890:Anti-Infective Agents; D001372:Aza Compounds; D024841:Fluoroquinolones; D011804:Quinolines; D000077266:Moxifloxacin